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Abstract 
The last few decades have produced a large number of proof-of-concept studies in regenerative medicine. 
However, the route to clinical adoption is fraught with technical and translational obstacles that frequently 
consign promising academic solutions to the so-called “valley of death.” This review is intended to serve as a 
blueprint for translational regenerative medicine: we suggest principles to help guide cell and material 
selection, present key in vivo imaging modalities and argue that the host immune response should be 
considered throughout therapeutic development. Finally, we suggest a pathway to navigate the often 
complex regulatory and manufacturing landscape of translational regenerative medicine. 
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Regenerative Medicine: A Key Curative Strategy for the 21st Century 
The great success of vaccines, antibiotics, statins and other major therapies have reshaped the landscape of 
preventative and curative medicine. In particular, the aging population demographic has led to the rise of 
regenerative medicine, which typically employs combinations of cells, biomaterials and biomolecules in 
order to rejuvenate or replace damaged or diseased tissue (Figure 1). The development of clinically-viable 
regenerative therapies is challenging and thus, we sought to write guidelines based on our experiences as part 
of the UK Regenerative Medicine Platform. We outline key criteria for selecting cells and biomaterials, 
summarize the major clinical options for tissue assessment and provide a roadmap for navigating key 
immunological, regulatory, manufacturing and translational hurdles. We hope that these guidelines will 
enable researchers in the field to avoid the common pitfalls of translational regenerative medicine and aid in 
the design of smart, holistic strategies with improved prospects of clinical adoption.  
The Regenerative Potential of Cells 
Cells as Regenerative Agents 
Natural cellular processes can be used as inspiration for regenerative medicine. During embryogenesis and 
post-natal growth, stem and progenitor cells generate specialized progeny that build and maintain tissues by 
cellular assembly, extracellular matrix (ECM) secretion and enzymatic remodeling. Normal wound healing is 
also regulated by coordinated cellular processes: the first responders to injury are platelets and neutrophils, 
which aggregate at the wound site and release growth factors and chemoattractants that trigger the 
recruitment of macrophages, lymphocytes, fibroblasts and endothelial cells. These cells remove damaged 
tissue and populate the wound site with a collagenous granulation tissue that is gradually remodeled into 
vascularized ECM (1). The processes involved in development and wound healing highlight the regenerative 
potential of cells. These natural precedents offer insights into how we can repair damaged tissue and provide 
a rationale for therapies that seek to replace diseased or damaged cells, or modulate the host environment to 
promote endogenous regeneration.  
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The biological complexity underpinning tissue regeneration necessitates a careful selection process guided 
by both technical and practical considerations. A first criteria is whether cells are sourced from the patient 
(autologous) or a donor (allogeneic). Allogeneic therapies are attractive if cells can be readily sourced and 
used “off-the-shelf,” however, the risks of immune rejection and iatrogenic infection mean that autologous 
therapies are often preferred for translation, even if these cells retain some of the defects that originally led to 
the disease in that individual. A second criteria is whether to use like-for-like cell replacement, such as 
autologous chondrocyte implantation for the repair of cartilage defects (2), or to employ cells out of context, 
such as the injection of skeletal myoblasts for cardiac regeneration (3). A third criteria is whether to use 
committed cell types, already specialized and functional, or stem cells that have the capacity for prolonged or 
unlimited self-renewal under controlled conditions and the potential to secrete a range of factors and 
differentiate into a variety of specialized cell types. 
Mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs) are 
examples of cells that exhibit multipotency; the capacity to differentiate into a small subset of cell lineages 
(4). A common alternative are cells that exhibit pluripotency; the ability to differentiate into any cell of the 
three germ layers (endoderm, mesoderm, ectoderm). Embryonic stem cells (ESCs) are naturally pluripotent 
but are restricted by their allogenic and ethically-controversial cell source. Meanwhile, induced pluripotent 
stem cells (iPSCs) can be generated by reprogramming autologous somatic cells, such as fibroblasts (5) or 
other abundent cell types (6). The controlled in vitro differentiation of iPSCs has enabled the derivation of a 
wide range of therapeutic cell types that would be otherwise challenging to source. However, a clinical 
hurdle in using iPSCs and ESCs is the inherent tumorigenicity associated with pluripotency, either through 
benign teratoma formation of undifferentiated cells or malignant transformation of differentiated progeny 
(7). 
Redefining the Cellular Role 
Induced pluripotency radically redefined our understanding of cell state and offered a striking example of 
cell plasticity: the concept that cells can readily adopt different phenotypic identities. This viewpoint sparked 
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intensive research into reprogramming strategies that converted somatic cells without the need for an iPSC 
intermediate. One method appeared to show that a brief pulse of Yamanaka factors could create a transient 
cell state that could be biochemically differentiated to various progeny, however, it is unclear whether this 
method truly bypasses pluripotency (8). Another approach involves somatic cell reprogramming using 
lineage-specific transcription factors, which has been used to generate a variety of regenerative cells, such as 
cardiomyocytes (9), neurons (10), and hepatocytes (11). These “transdifferentiation” strategies are restricted 
by low yields and the lack of cell rejuvenation, however, they do offer a cheaper and faster route than iPSCs 
for deriving regenerative cell lines and, to date, appear to mitigate the inherent risk of tumorigenicity 
associated with pluripotent cells (12). 
A major consideration for the translation of pluripotent cells (ESCs and iPSCs) is the emergence of 
potentially dangerous genetic and epigenetic variants. In vitro culture creates bottlenecks, such as post-
plating survival, cell-cycle checkpoints and post-mitotic survival of daughter cells, which favor cells with 
certain acquired mutations, such as copy-number variants overexpressing BCL2L1 (13). This genetic 
variance can result in aberrant lineage specification, growth factor and niche independence, and increased 
frequency of tumor-initiating cells (14). Moreover, loss of genomic imprinting and erosion of chromosome 
inactivation can arise during pluripotent stem cell culture (15, 16). Such culture-induced perturbations 
represent a latent safety risk for ESC and iPSC therapies. Accordingly, there has been a focus on screening 
clonal cell lines to understand and catalog the functional significance and risk associated with such changes 
(e.g., tumorigenesis), in order to aid the development of culture conditions that could slow the emergence of 
variant cells (17). 
A number of studies have indicated that screening can also be used to identify cell subpopulations with 
enhanced regenerative potency. For instance, Dickinson et al. used fluorescence-activated cell sorting to 
isolate a subset of highly chondrogenic human MSCs, which were used to provide quantitatively improved 
outcomes in the treatment of articular cartilage defects (18). In another example, Kirkeby et al. performed a 
large-scale analysis into the global gene expression profile of human ESC-derived dopaminergic 
neuroprogenitors on the day of intrastriatal transplantation in a rat model of Parkinson’s disease. Predictive 
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markers expressed by midbrain dopaminergic neurons close to the midbrain-hindbrain boundary region 
correlated with a successful graft outcome, while markers expressed in the diencephalic domain were 
negatively associated (19). Such studies can aid in the identification of optimal culture protocols, improve 
clinical reliability through reduction of biological variability, help to define acceptable levels of genetic 
variance in cell-based products, and offer a quality control, defined release assay for cells that need to 
differentiate in vivo for efficacy. 
Orchestrating Regeneration 
Interactive and Dynamic Biomaterials 
Stem cells reside in distinct anatomical microenvironments, known as niches, in which the surrounding 
ECM, soluble factors, immobilized biochemicals and local niche cells present a dynamic array of signals that 
instruct the resident cells to remain quiescent, undergo self-renewal, differentiate, or die (20). Regenerative 
biomaterials are typically designed to play a similar functional role, interacting with interfaced cells and the 
host environment in order to elicit targeted biological responses. This can be guided by cell-material 
interactions that can be nonspecific (e.g., electrostatic binding, lipid anchoring) or specific (e.g., ligand 
binding to integrins or organized proteoglycan domains) (21, 22). The cellular interaction of biomaterials can 
also be tuned by modulating protein adsorption. For example, hydrophobic materials can be used to adsorb 
albumin, an abundant serum protein that blocks cell adhesion, while slightly hydrophilic substrates can be 
used to adsorb fibronectin, a cell-binding protein (22).  
Cell-material interactions are also guided by interfacial geometry. It is widely accepted that biomaterials that 
offer a 3D network, such as microfibrous scaffolds or nanofibrous hydrogels, can provide a more biomimetic 
cell culture environment than 2D substrates (23). Moreover, topographical cues provide an effective means 
to regulate adhesion, migration, differentiation, epigenetic state or cell reprogramming (24). Many of these 
biological responses are achieved by mechanosensing, in which the interfaced cells respond to extracellular 
forces through deformation, mechanosensitive ion channel activation, or integrin binding and signal 
transduction (25). For instance, cells originating from softer tissues (e.g., neural) can show improved 
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biological response when cultured on low-stiffness biomaterials (26). These observations have popularized 
the use of biomaterials with tissue-matched mechanical properties, however, this approach often overlooks 
the complex changes in tissue mechanics that occur during physiological development (27). In this regard, 
biomaterials that provide spatial and temporal differences in substrate mechanics can provide a more natural 
biological response (28, 29). 
Biomaterials that can undergo dynamic phase changes are also widely used in regenerative medicine; 
consider the different transitions exploited in bioprinting (30), micromolding (31) and biomaterial injection 
(32). Meanwhile, controlled degradation can be used to enhance the maturation of engineered tissues or 
release cargo from biomaterial vectors. This can be achieved by using synthetic biomaterials that slowly 
hydrolyze into non-toxic byproducts, while additional control can be leveraged by using biomaterials 
susceptible to enzymatically-catalyzed degradation (33). For example, cartilage engineered using 
chondrocyte-laden agarose can be cultured with agarase to degrade the hydrogel and provide the growing 
tissue with additional space for nutrient diffusion and matrix assembly (34). Another example is the use of 
materials crosslinked with peptides subsequently cleaved by specific catabolic enzymes. This approach can 
be used in regenerative medicine to create drug delivery systems that are responsive to particular in vivo 
environments (e.g., inflammation), or biomaterial systems with programmed degradation profiles for in vitro 
tissue engineering (33). 
Immunology and Regenerative Medicine 
The Host Immune Response 
Vertebrates have evolved an innate and an adaptive immune system that aims to eliminate invading 
pathogens, toxic substances and allergens without causing harm to the host. Innate immunity is an ancient 
defense mechanism found in all multicellular organisms and involves a non-specific inflammatory response 
after recognition of a foreign substance (35). Many pathogens exhibit conserved pathogen-associated 
molecular patterns that can be recognized by immune cells bearing pathogen recognition receptors (36). 
Upon detection of a foreign body, the innate immune system initiates phagocytosis, apoptosis, opsonization 
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and the activation of pro-inflammatory signaling pathways (35, 36). Adaptive immunity is a highly-specific 
antigen response that provides long-term immunological memory via either cell-mediated or antibody-
mediated (humoral) immunity (37). Adaptive immunity involves the activation of T cells, B cells and natural 
killer cells, while innate immunity is regulated by polymorphonuclear cells and mononuclear phagocytes, 
such as dendritic cells, monocytes and macrophages. 
The immune system is implicated in many diseases targeted by regenerative medicine, moreover, the 
recognition and elimination of foreign entities by the host immune system presents several issues for 
therapies that involve the administration of exogenous cells, tissues or biomaterials. For instance, non-
autologous cells can activate the host adaptive immune system through either direct or indirect 
allorecognition, leading to cell-mediated or antibody-mediated cytotoxicity (Figure 2A) (38). The severity of 
the initial allorecognition response scales with the degree of antigen mismatch between the donor and 
recipient cells. Major histocompatibility complex (MHC) matching between the donor and recipient is used 
clinically to mitigate allorecognition, however, even well-matched donors are capable of provoking 
unwanted immune responses (39). Critically, therapies based on autologous hiPSCs can also elicit an 
immune response, potentially due to the use of relatively immature cells or the effect of cell reprogramming, 
xenogeneic supplements and/or non-physiological culture conditions (40). 
An immune response can also be elicited by the implantation of acellular or cellularized biomaterials (41). 
Many regenerative therapies require the implanted biomaterial to integrate with the surrounding environment 
to provide long-term restoration of biological function. In reality, implanted biomaterials often provoke a 
host immune response, known as a foreign-body reaction, that can hinder integration and functional 
performance (42). Initially, a blood-biomaterial interaction leads to the formation of a protein film and 
provisional matrix at the biomaterial surface, which is then followed by acute and chronic inflammation. At 
this stage, macrophages fuse to produce foreign body giant cells, granulation tissue is deposited and then a 
fibrotic capsule is formed around the biomaterial (Figure 2B). It should be noted that the foreign-body 
reaction is a chronic pathology and thus more of an issue for long-term, nondegradable grafts rather than 
transient or biodegradable materials. 
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Evading or Harnessing the Immune System 
The nature and magnitude of the host immune response to a regenerative therapy is dependent on several 
factors, such as the properties of the cell or biomaterial, the implant location and the environmental 
conditions. For instance, while many cell types commonly provoke a host immune response, other cell types 
are thought to provide a level of immunosuppression (43). Meanwhile, the immunogenicity of a biomaterial 
can be affected by a number of properties, such as porosity, surface chemistry, size and shape (44). Given 
these complexities, it is evident that a holistic understanding can allow the design of regenerative therapies 
that are compatible with the host immune system. Classically, this has involved the design of immune 
evasive therapies that attempt to circumvent the immune response in order to allow the implanted therapeutic 
to perform its intended role with minimal interference from the host. 
For example, the initial allorecognition response can be mitigated by using biomaterials with certain 
properties; a well-known example is the harnessing of hydrophilic polymer coatings to attenuate recognition, 
opsonization and clearance (45). Biomaterial cell encapsulation can also be used to provide a physical barrier 
that aims to limit direct cell-cell interactions with the host immune system (46). An elegant, biological 
approach is the use of cells derived from iPSCs isolated from immune-privileged sites, which appear to 
retain an epigenetic memory of immune evasion (47). Moreover, recent work has shown that inactivation of 
MHC classes I and II, combined with overexpression of CD47, produces hypoimmunogenic iPSCs that can 
avoid rejection in allogeneic hosts (Figure 2C) (48). Other approaches include the inhibition of T-cell 
activity using pharmacological or cell-based immunosuppression, the genetic modification of cells to express 
tolerogenic antigens or remove immunogenic epitopes, or the immunization of the host to specific cell-
surface markers (38). 
These examples highlight the classic view that the immune response should be suppressed or evaded during 
therapy. However, the immune system can also be a fundamental orchestrator of tissue repair, with many 
regenerative processes regulated by macrophages, a heterogeneous cell population with a dynamic 
phenotype that resides between a pro-inflammatory (M1) state and an anti-inflammatory (M2) state. This 
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cellular plasticity is driven by environmental signals and is central to both the formation and degradation of 
scar matrix (49). These features have prompted the design of immune-interactive biomaterials with the aim 
of polarizing macrophages towards the M2 phenotype (Figure 2D) (50). Materials can also be used to 
deliver pro-regenerative factors: for instance, gold nanoparticles decorated with interleukin-4 have been used 
to direct M2 polarization of macrophages and improve the function of injured muscle (51). These, and other 
findings, offer a fresh perspective on how immunomodulation can be an intrinsic component of regenerative 
medicine. 
Measuring & Visualizing Tissue Regeneration 
In Vivo Tissue Profiling  
In vivo imaging has revolutionized disease diagnosis and monitoring by offering invaluable tools that can 
assess tissue status in a minimally-invasively, quantitative, and spatiotemporal manner. Magnetic resonance 
imaging (MRI), computed tomography (CT) and ultrasound (US) are the clinical state-of-the-art for 
visualizing structural, functional, molecular and mechanical tissue properties, and can be used in 
preclinical/clinical trials of regenerative therapies. For instance, multimodal MRI has been used to measure 
the impact of intramyocardial stem cell injections on scar size, tissue perfusion and circumferential strain in 
patients with heart disease (52). Meanwhile, emerging modalities present new opportunities for in vivo 
interrogation of regenerative mechanisms. For example, hyperpolarized 13C MRI can increase sensitivity by 
40,000-fold compared to standard MRI (53). This has enabled the metabolism of injected labelled 
metabolites to be visualized clinically (54), offering the possibility for linking new metabolic diagnostic 
biomarkers to degeneration and repair. 
Optical coherence tomography and confocal microscopy offer a clinical imaging route for assessing retinal 
or corneal regeneration (55, 56). However, visible light is highly absorbed and scattered by most biological 
tissues, compromising the spatial resolution of light-based methods for deep-tissue imaging. However, by 
combining optical excitation with US detection, photoacoustic imaging (PAI) enables high-resolution, deep-
tissue imaging with clear potential for clinical translation (57). This exploits the photoacoustic effect, in 
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which molecular absorption of incident photons triggers a thermally-induced pressure jump that releases US 
waves. PAI has been used to evaluate vascular reperfusion, blood oxygenation and whole-brain neural 
activity in small animal disease models (58, 59). An exciting development for resolving dynamic tissue 
processes is four-dimensional functional US imaging, which can provide volumetric recordings at high 
spatiotemporal resolution. This has been used to evaluate neural connectivity and map whole-brain wave 
propagation (60), thus providing new opportunities for measuring the efficacy of neuro-regenerative 
therapies. 
In Vivo Monitoring 
Resolving the fate of an administered therapeutic, including bio-distribution, engraftment, migration, 
embolism and clearance, is essential for understanding the mechanism, technical constraints and safety 
profile of a regenerative strategy. In vivo imaging can be adapted to visualize implanted therapeutics, such as 
the CT-based monitoring of high-contrast biomaterials (e.g., ceramics) (61) or repair processes (e.g., bone 
ingrowth into an implanted scaffold) (62). However, therapies involving smaller entities (e.g., cells, particles, 
extracellular vesicles, biomolecules) generally require a more sensitive imaging modality. One option is 
nuclear imaging of therapeutics labeled with radionuclides that either release γ-rays for single-photon 
emission computed tomography (SPECT), or positrons that annihilate with electrons in the host tissue to 
produce γ-rays for positron-emission tomography (PET) (63). In each case, it is important to use 
radiolabeling methods that provide high contrast across the imaging period, without the radionuclide 
dissociating, causing significant toxicity or altering the performance of the therapeutic entity. 
Radiolabeling small molecules and proteins typically involves covalent or electrostatic binding (64), while 
non-specific metabolic radiotracers can be taken up by cells, which has been used to track the fate of 
administered peripheral-blood CD34+ cells (65) and the engraftment of islet cells (66). Targeted approaches 
can provide process-specific readouts, for instance, 18F-dihydroxyphenylalanine can traverse the blood-brain 
barrier and be taken up by presynaptic terminals of dopaminergic projections, providing information 
regarding the survival and maturation of transplanted dopaminergic neurons (67). Similarly, a radiolabeled 
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dopamine D2 receptor antagonist, 11C-raclopride, can be used to visualize synaptic dopamine release from 
stimulated, transplanted neurons (68). Alternatively, the stable integration of reporter genes into the genome 
(e.g., using lentiviral transfection) provides the opportunity to track cells in the body over long periods of 
time. For instance, the expression of an enzyme (HSV-TK1) that selectively traps 18F-fluoro-3-
[hydroxymethyl]butyl)guanine can be used to provide cellular contrast with PET (69). The recent 
introduction of high-sensitivity, whole-body PET scanners have been used clinically with reduced imaging 
time and radionuclide dose, offering greater ease for monitoring regenerative therapeutics in patients 
compared to current scanner designs (70). 
Delivering Patient Benefit: Clinical Translation 
A Blueprint for Translational Medicine 
The last two years has seen the publication of results from several promising clinical trials (Table 1). In 
phase I clinical trials, Moroni et al. established the safety profile of peripheral infusions of autologous 
monocyte-derived macrophages in nine patients with compensated liver cirrhosis (71). Da Cruz et al. 
reported improvements in visual acuity and no significant safety issues following the implantation of 
synthetic membranes, seeded with human ESC-derived retinal pigment epithelium, in two patients with age-
related macular degeneration (72). Curtis et al. reported no adverse effects, and early indications of 
therapeutic efficacy, after local delivery of human NSCs in four individuals with spinal cord injury (73). 
Meanwhile, clinical investigation of iPSC-derived retinal pigment epithelium as a treatment for macular 
degeneration (74) has been followed by iPSC-based clinical trials for a range of indications, including 
corneal disease (75), spinal cord injury (76), and Parkinson’s disease (77). 
The success of these trials, and other translational studies, will be determined by a variety of factors. 
Ultimately, the most important aspect of translation is the demonstration of robust patient safety and efficacy 
through preclinical and clinical trials. However, even safe and efficacious therapies can be thwarted by other 
translational pitfalls; products may be cost ineffective and not competitive against current therapies, 
challenging to manufacture at scale, or restricted by regulatory requirements in a particular sector or market. 
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Here, we provide a blueprint for translation of academic ideas into clinical regenerative medicine, focusing 
on key stages and milestones that researchers should address in the early stages of translation in order to 
build a strong basis for product development and the compilation of a technical file for regulatory 
submission (Figure 3). To provide context, we also discuss later translational stages, although by this stage, 
activity will typically have transferred from academic to an industrial setting (licensing or start up). 
Commercial Considerations 
Translating a regenerative therapy is expensive: in the United States of America (USA), it can cost US$150-
250 million to take a cell-based product through phase III clinical trials (78). Although there are established 
business models for translational regenerative medicine (79), the associated costs and risks dictate that 
capital investment is almost always required. However, many venture capitalists are justifiably wary after the 
high-profile failures of the 1990s, in which several tissue engineering products were unprofitable despite 
being shown to be safe and efficacious (80). Steps should be taken to ensure freedom to operate (FTO) in the 
desired area and to protect intellectual property (IP). Since these factors can greatly influence the technical 
components of a proposed strategy, such as cell line selection, researchers should engage technology transfer 
teams early in the translational process to review FTO and establish IP strategy before publishing any details 
of the invention. 
It is also important to establish whether the translational product will meet an “unmet need.” Clinicians must 
be consulted and competitor reviews performed to ascertain the advantages of the proposed therapy over the 
current standards of care and competing systems. This assessment should be carried out at the early stages of 
translation and must cover the treatment pathway as well as clinical outcomes and product costs. Will the 
proposed product be available “off-the-shelf”? Would the proposed mode of delivery reduce costs of 
invasive surgery and associated complications? Could the proposed therapy be used to treat a broader 
spectrum of patients? These practical considerations form the basis of the cost-effectiveness of a proposed 
solution and will greatly influence the design of the final product. This is important as the decision makers 
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for product adoption assess products on economic benefits in their healthcare setting, rather than on clinical 
promise. 
Regulatory Considerations 
In the USA, products are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps), 
devices, biologics or drugs based, in part, on their “primary intended purposes” (78). The European Union 
(EU) has a similar classification of advanced therapy medicinal products (ATMP), medical devices or 
medicinal substances based on the “principal intended action” (81). These classifications determine the 
applicable regulations and are relatively easily applied to single-part therapies, such as acellular scaffolds. 
For multi-component systems, such as cell-seeded scaffolds, the legal manufacturer must comply with 
applicable regulatory requirements for all components. While the regulations are necessarily stringent, 
schemes such as the Breakthrough Therapy designation (USA), the Regenerative Medicine Advanced 
Therapy designation (USA), the Sakigake designation (Japan), and the PRIME initiative (EU) are available 
to support patient access to innovative medicines with high public health potential (82). Regulatory strategies 
should ideally be devised in consultation with a regulatory expert, once the unmet need and intended use 
have been defined. 
Preclinical and Clinical Studies 
Before a product can be authorized for market release, the legal manufacturer must demonstrate safety and 
efficacy for its intended use, in the intended population, for the intended purpose. In the early stages, 
researchers should clearly define these clinical parameters (intended use, population, purpose), how the 
proposed product achieves a therapeutic effect, and the expected benefits over available alternatives. These 
claims must, ultimately, be validated by clinical data using endpoints that can quantifiably measure whether 
the patient undergoing treatment lives longer and/or better than if they received the gold standard therapy or 
no treatment at all. Real clinical endpoints include higher overall survival, reduced patient symptoms, or 
improved quality of life (83). Surrogate endpoints, such as disease-free survival and progression-free 
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survival, can also provide useful indication of therapeutic efficacy, however, care should be taken as these 
factors may not necessarily correlate with real clinical endpoints (83). 
Clinical studies should be designed in collaboration with clinicians and statisticians, and aided by a 
systematic review of relevant clinical data. Ideally, preclinical tests are performed using well-validated, high-
fidelity animal models that in some way mimic the clinical problem. However, accurate modelling can be 
restricted by differences in physiology, anatomical size, and disease characteristics between animal models 
and human patients. In addition, preclinical testing with human cells requires immunocompromised animals, 
which can cause problems when studying long-term effects (>6 months) (84). For clinical testing (i.e., in 
humans), proposed therapies must progress through a carefully staged process. Initial studies are performed 
on a small number of participants to test for tolerability and feasibility (phase I), then larger groups are used 
to test for any signal of therapeutic efficacy (phase II), which is then formally compared to the current 
standard of care (phase III). Further clinical studies are performed after approval, in order to track long-term 
benefits and side effects (phase IV). 
Manufacturing Considerations 
Successful translation requires manufacturing processes that can be performed reliably and at scale, while 
remaining financially viable. Unfortunately, the manual handling protocols commonly used in academia can 
present high technical variability, the risk of contamination, a lack of precision or power, and low throughput 
production. Moreover, manually-operated systems require expertise knowledge and training. Given these 
limitations, it is important that automated and mechanized processes are employed, where possible, during 
product manufacture. Automation uses machines to replicate manual processes, which can greatly reduce 
technical variance, production costs and the risk of contamination. Automated systems can also benefit from 
mechanization, in which machines outperform humans in precision, power or throughput (85). Reliability 
can be improved through other means: by employing strict standard operating procedures, chemically-
defined and batch-tested media of good manufacturing practice (GMP) standard, closed cell systems and 
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batch segregation to limit microbial or chemical contamination, and culture protocols known to reduce 
genetic or epigenetic variability (86).  
Harmonized standards are available to support manufacturers in establishing quality management systems 
(QMS) that can be implemented throughout product development and production. In particular, this 
framework of quality assurance practices can aid in documenting the design history, product requirements, 
applicable standards and state-of-the-art test methods, and in performing initial risk assessments, maintaining 
traceability, characterizing products and monitoring manufacturing processes. For example, it is 
recommended that cell and tissue culture is performed using bioreactors with integrated sensors that 
continuously record the media pH, glucose concentration and dissolved oxygen levels (87). These online 
monitoring systems, and other analytical methods, should be used to generate critical-to-quality (CTQ) 
attributes. These quantitative metrics are used for product quality control to assess whether changes in 
critical process parameters (CPP) produce statistically significant differences in safety or efficacy. 
Equivalence testing should be performed for all process changes, including alterations in protocol, materials, 
equipment or manufacturing location (88). 
One process change that should not be underestimated during early development is scaling: therapies can 
require hundreds of millions of cells per dose, and manufacturers often need to navigate hurdles of large-
scale cell expansion (senescence, dedifferentiation, slow proliferation, infrastructure) (89, 90). Scalable cell 
expansion can be facilitated by automated and mechanized processes, closed cell systems and intermediate 
cryopreservation stages (89, 90). Production rate can then be raised either by scale-out, which involves an 
increase in the number of units (e.g., bioreactors) with maintained output per unit, or by scale-up, whereby 
the output per unit is increased. Scale-out is a more predictable process change with additional flexibility 
over production rate and reduced operating risk, however, scale-up may be more appropriate for allogeneic 
therapies or highly mechanized manufacture (90, 91). To avoid unnecessary operational costs, manufacturing 
processes should be designed to be scalable but only scaled in line with clinical trials size or market demand 
(91). 
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Risk Management 
Regulations require risk assessments for the whole product, each individual part and any interactions that 
may occur between components. For example, an engineered graft should be considered in terms of the 
whole tissue, its constituent cells, materials and biomolecules, as well as any interactive processes (e.g., 
adhesion, signaling). Technical risks include malignant transformation, component toxicity, disease 
transmission, immune rejection, and the increased risk of thromboembolic disease, while extrinsic risks can 
arise during procurement, delivery, handling, storage, surgery, or immunosuppression (92). Given the variety 
of different factors, it is important to assemble a risk assessment team during the early stages of translation, 
and include technical, clinical, regulatory and manufacturing expertise to effectively identify, score, and pre-
emptively mitigate potential risks by design. This can be supported by performing an early review of 
scientific literature, including failure reports and national registry data for similar therapies. An effective risk 
management strategy, implemented throughout the course of a project, can help avert setbacks that can 
consign an idea to the translational “valley of death.”  
Future Perspectives 
These are truly exciting times for regenerative medicine, at the confluence of cutting-edge biological 
manipulation (e.g., iPSCs, CRISPR/Cas9, optogenetics), powerful in vitro models (e.g., organoids, organ-on-
a-chip, 3D bioprinting, machine learning) and advanced characterisation tools (e.g., spatially-resolved omics, 
super-resolution microscopy, machine learning) (93). We must strive to use such innovative methods to 
improve our understanding of disease targets, better resolve the fate of implanted therapeutics and unravel 
the mechanisms underpinning tissue regeneration. These outcomes should provide solid scientific 
foundations for the major challenge of the field: to assemble efficacious, reproducible and scalable therapies 
that offer programmed tissue regeneration within a robust regulatory and manufacturing pipeline. We hope 
that the biological, material, immunological, imaging and translational aspects that we have highlighted in 
this review can serve as a blueprint for those seeking to turn academic ideas into clinical regenerative 
medicine products providing real patient benefit. 
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Tables  
Table 1. Selection of published clinical trials of regenerative therapies since 2018 
Indication Trial Details Regenerative Therapy Reference 
Macular 
degeneration 
- Phase I 
- 2 patients 
Human iPSC derived retinal pigment 
epithelium delivered on a PET membrane. 
L. Da Cruz et al. Nat. 
Biotechnol. 2018 (72) 
Thoracic spinal 
cord injury 
- Phase I 
- 4 patients 
Human NSCs (NSI-566) injected locally 
using a stereotactic floating cannula. 
E. Curtis et al. Cell Stem 
Cell 2018 (73) 
Ischemic  
stroke 
- Phase I 
- 9 patients 
Intra-carotid artery transfusion of 
autologous CD34+ cells in the infarct area. 
P.-H. Sung et al. Am. J. 
Transl. Res. 2018 (94) 
Rheumatoid 
arthritis 
- Phase I/II 
- 15 patients 
Intra-articular injection of cultured, 
autologous mesenchymal stem cells. 
S. Shadmanfar et al. 
Cytotherapy 2018 (95) 
Compensated 
liver cirrhosis 
- Phase I 
- 9 patients 
Peripheral infusion of matured autologous 
monocyte-derived macrophages. 
F. Moroni et al. Nat. 
Med. 2019 (71) 
Knee 
osteoarthritis 
- Phase 2 
- 26 patients 
Intra-articular injection of cultured, 
autologous mesenchymal stem cells. 
L. Lu et al. Stem Cell 
Res. Ther. 2019 (96) 
Compensated 
liver cirrhosis 
- Phase 2 
- 81 patients 
Subcutaneous delivery of granulocyte 
colony-stimulating factor and intravenous 
infusion of CD133+ HSCs. 
P. N. Newsome et al. 
Lancet Gastroenterol. 
Hepatol. 2018 (97) 
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Figure Legends 
Figure 1. Overview of some common strategies, components and interactions used in regenerative medicine. 
Cells, biomaterials and biomolecules exhibit a number of interdependent interactions that can be exploited 
for various regenerative medicine strategies, including tissue engineering, drug delivery, immunomodulation 
and genetic engineering. 
Figure 2. The host immune response and regenerative medicine. (A) Direct allorecognition occurs by 
cytotoxic T cells (Tc cells) recognizing and eliminating allogeneic donor cells, while indirect allorecognition 
occurs by helper T cells (Th cells) recognizing donor antigens taken up and displayed by host antigen-
presenting cells. (B) Implanted biomaterials can provoke a foreign body reaction resulting in the formation 
of a fibrous capsule containing both macrophages and foreign body giant (FBG) cells. (C) An example of 
immune evasion, in which transgene expression and CRISPR/Cas9 are used to generate hypoimmunogenic 
hiPSCs with upregulated CD47 but neither class of MHC (B2m-/- and Ciita-/-). (D) An example of immune 
modulation, in which ECM-derived biomaterials recruit T helper 2 cells (Th2 cells), which secrete cytokines 
that can polarize macrophages to an M2-like phenotype. In turn, these alternatively-activated macrophages 
secrete cytokines that sustain Th2 cell activation. 
Figure 3. Bench-to-bedside translation of regenerative medicine products. Translating an academic concept 
into a clinical product can be divided into three key stages: early research and development, pre-clinical 
product development and clinical studies. This schematic predominantly focuses on the technical aspects 
that should be considered by scientists at early technology readiness level (TRL), with higher TRL items 
included for context. Highlighted are the key tasks (yellow boxes), systematic quality control to fulfill all 
applicable requirements (blue boxes) and critical checkpoints that should be met throughout product 
translation (orange boxes), with each stage guided by experts in the field. The timeline of this schematic 
should not be considered an absolute scale, indeed, the relative time and work required at the different stages 
will vary considerably depending on the product or therapy that is being translated. It should also be noted 
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that in the EU, good manufacturing practice (GMP) is applicable for medicines and ATMPs but not for 
medical devices. 
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